Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs HuMax IL8 (Primary) ; Nivolumab (Primary) ; Degarelix
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MAGIC-8
- 17 Jan 2019 Planned initiation date changed from 1 Oct 2018 to 1 Mar 2019.
- 17 Jan 2019 Status changed from not yet recruiting to recruiting.
- 04 Oct 2018 New trial record